At a glance
ClinicalIndex Comparison RecordN/ACompleted· 129 enrolled
Drug / intervention
SENTRY IVC Filterdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multi-Center Study of the Novate Sentry Bioconvertible Vena Cava Filter
In Brief
A clinical study evaluating SENTRY IVC Filter for Pulmonary Embolism and Deep Vein Thrombosis. Completed, enrolled 129 participants across 23 sites in 3 countries.
Detailed Summary
The SENTRY Bioconvertible Inferior Vena Cava (IVC) Filter has been developed to provide temporary protection against pulmonary embolism (PE).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Embolism, Deep Vein Thrombosis
CountriesBelgium, Chile, United States
CollaboratorsNovate Medical
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartSep 2014
Primary CompletionAug 2016
Study CompletionDec 2018
TodayJul 2026
First PostedNov 4, 2013
Enrollment StartSep 1, 2014
Primary CompletionAug 1, 2016
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.7 years ago
Interventions
SENTRY IVC Filterdevice
The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.